SCHEMBL370666

SCHEMBL370666

COc1ccc(Cn2cc(-c3nc(Nc4nccc(C)n4)sc3Cl)cn2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.43
GRM8 O00222 1/20 0.43
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
ADORA1 P30542 1/20 0.39
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
TTK P33981 1/20 0.38
TGFBR1 P36897 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
PKM P14618 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CLK1 P49759 2/20 0.36
CLK2 P49760 2/20 0.36
DYRK1A Q13627 2/20 0.36
CLK4 Q9HAZ1 2/20 0.36
DYRK1B Q9Y463 2/20 0.36
POLQ O75417 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2509685 0.91 ADORA2A (0.41) ADORA2AADORA2BADORA1CCNA2CDK2
SCHEMBL368791 0.89 GRM4 (0.41) GRM4GRM8ADORA2AADORA2BADORA1
SCHEMBL369661 0.88 GRM8 (0.41) GRM4GRM8ADORA2AADORA2BADORA1
SCHEMBL2504661 0.88 GRM4 (0.41) GRM4GRM8ADORA2AADORA2BADORA1
SCHEMBL369662 0.86 GRM4 (0.40) GRM4GRM8ADORA2AADORA2BADORA1
SCHEMBL370432 0.83 RAB9A (0.45) NPC1RAB9ASMN1; SMN2GAAMEN1
SCHEMBL3356253 0.83 MEN1 (0.45) GRM4ADORA2AADORA2BADORA1L3MBTL1
SCHEMBL1051534 0.77 ADORA2A (0.44) ADORA2AADORA2BADORA1L3MBTL1NPC1
SCHEMBL1051684 0.76 PIK3CD (0.44) ADORA2AADORA2BADORA1L3MBTL1NPC1
SCHEMBL3353868 0.75 GRM4 (0.53) GRM4ADORA2AADORA2BADORA1TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130210809-A1 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS BOLEA CHRISTELLE (CH) 2013-08-15 US disclosed
EP-2595986-A2 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharma SA (CH) 2013-05-29 EP disclosed
WO-2012009009-A2 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210809-A1 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM2, GRM4, GRM1 GRM4 2/4885GRM8 23/4885ADORA2A 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.